Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04975256 · ClinicalTrials.gov registry record · Phase 1
Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)
A Phase 1 study, sponsored by Mirati Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT04975256 is a Phase 1 study that was terminated before completion, run by Mirati Therapeutics. The registered enrollment target is 7 participants.
The verdict
NCT04975256, a Phase 1 study, was terminated before completion, sponsored by Mirati Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This study will evaluate safety, tolerability, drug levels, molecular effects and clinical activity of MRTX849 (adagrasib) in combination with BI 1701963 in patients with advanced solid tumors that have a KRAS G12C mutation.
Interventions
- DRUG MRTX849
- DRUG BI 1701963
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2021-07-28 |
| Est. Completion | 2022-11-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04975256
The ClinicalTrials.gov registry entry for NCT04975256 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mirati Therapeutics, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MRTX849 is the first listed.
NCT04975256 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04975256 about?
NCT04975256 is a clinical study titled "Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)". This study will evaluate safety, tolerability, drug levels, molecular effects and clinical activity of MRTX849 (adagrasib) in combination with BI 1701963 in patients with advanced solid tumors that have a KRAS G12C mutation.
What is the current status of trial NCT04975256?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2021-07-28. Estimated completion is 2022-11-15.
What interventions are being tested in trial NCT04975256?
The interventions under investigation include: MRTX849 (DRUG), BI 1701963 (DRUG).
Who is sponsoring clinical trial NCT04975256?
This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.